Anticoagulant Maker XO1 Takes $11M In Index Ventures’ Largest Series A

A chance discovery at a U.K. hospital led to the synthesis of an antibody that could prevent blood clots without causing excessive bleeding. Index Ventures created and funded single-asset company XO1 to conduct first-in-man tests on the compound by 2015.